The Central Drugs Standard Control Organisation (CDSCO) reported 111 substandard drug samples in November, with 41 from its central lab and 70 from state labs. Additionally, two spurious drug samples, Pantoprazole and Amoxycillin, were identified. CDSCO emphasizes that this only affects the specific batches tested and urges stakeholders to maintain regulatory standards.
